Highlights
• Convatec appoints former Fortrea finance chief Jill McConnell as Chief Financial Officer Designate from 1 January 2027.
• McConnell becomes CFO and joins the Board on 1 March 2027, succeeding outgoing finance chief Fiona Ryder.
• Ryder stays through the 23 February 2027 full-year results and leaves the Business at February's end.
• Brian May becomes Senior Independent Director while Tobias Hestler takes the Audit and Risk Committee chair.
Convatec Group (LSE:CTEC) has found its next finance chief, ending a search that began in July. The FTSE 100 medical products group said on Tuesday that Jill McConnell, most recently chief financial officer of US-listed Fortrea, will join as CFO Designate in January and take the top finance Job in March. A second announcement minutes later reshuffled key Board roles, giving the company a refreshed line-up heading into 2027.
Who is Convatec's incoming CFO?
McConnell brings more than 25 years of finance Leadership across healthcare and life sciences. At Fortrea, a contract research organisation with revenues of over $2.5 billion, she helped establish the business after its 2023 spin-off from Labcorp. Her Labcorp roles included CFO of Labcorp Drug Development.
Before that, she spent almost two decades at GSK, where she served as CFO of its US pharmaceuticals business and CFO of ViiV Healthcare, and held positions in the UK and Ireland.
From 1 January 2027 she will report to Chief Executive Jonny Mason, join the Executive Leadership Team and attend Board meetings. On becoming CFO on 1 March 2027 she will lead Finance, Corporate Strategy and Development, Convatec Business Services and Investor Relations.
How the handover will work
Fiona Ryder will remain CFO through the publication of full-year results on 23 February 2027 and will leave at the end of that month, also stepping down from the Board. She joined Convatec in January 2022, acted as interim CFO from August 2025 and was confirmed in the role in November 2025. The company credits her with strengthening Finance, setting up Convatec Business Services and advancing its simplification and productivity agenda.
Mason said: "I'm delighted to welcome Jill to Convatec." He added that "Jill brings deep healthcare experience, especially from the US which is Convatec's largest market."
McConnell said: "The company has a clear strategy, strong momentum and a compelling purpose centred on improving patients' lives."
Pay package and Board changes
McConnell's base salary is $700,000. Her maximum annual Bonus is 200% of salary and her maximum long-term incentive award is 325% of salary. She will receive a net UK accommodation allowance of $40,000 a year and must build a shareholding worth 300% of salary. Notice periods are 12 months from the company and six months from her. Convatec said Ryder's departure terms are aligned with its approved Directors' Remuneration Policy.
The separate Director updates announcement confirmed that Brian May becomes Senior Independent Director and Tobias Hestler, former Group CFO at Haleon, becomes Chair of the Audit and Risk Committee, both with immediate effect. Each succeeds Margaret Ewing, who stays on the Board until retiring on or before the next AGM.
Why the timing matters
The appointment lands as Convatec enters what Mason called "the next phase of Accelerate", the group's strategy. The four-month window between McConnell's arrival in January and Ryder's exit in February gives the two executives an overlap that spans the year-end reporting cycle.
Risks and what investors may watch next
Any finance leadership change brings execution risk, especially when it straddles year-end reporting and a strategy rollout. Investors may watch the 23 February 2027 results, Ryder's final set, and McConnell's first public engagement as CFO after 1 March. Progress on the share buyback programme that began in August is another marker.
The Bottom Line for Convatec
Chair Dr John McAdam said Ryder "has made a substantial contribution to the business through its turnaround." With a successor named, a defined handover window and a refreshed set of committee leaders, the company has settled its top finance and governance roles well ahead of 2027.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...